When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ODT - Odonate under pressure on safety profile of lead drug tesetaxel
Odonate Therapeutics Inc.
Odonate Therapeutics (NASDAQ:ODT) says that the CONTESSA (Phase 3) trial evaluating lead candidate tesetaxel in metastatic breast cancer (MBC) patients met the primary endpoint of improved Progression-free Survival (PFS), with median PFS of 9.8 months for tesetaxel + reduced dose of capecitabine arm, vs. 6.9 months in approved doses of capecitabine alone.
More news on: Odonate Therapeutics, Inc., Healthcare stocks news, Stocks on the move,